Clinical trials
Hepatitis clinical trials
Below are recruiting hepatitis clinical trials, each written for real people, not researchers. We’re tracking 480 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07667101Recruiting
Hepatitis C team care for people in supportive housing
This study tests a team-based approach — a pharmacist, doctor, and patient navigator working together — to help people living in permanent supportive housing get hepatitis C care. If you have hepatitis C and live in DESC housing, the study will check how well this team helps you through treatment over 2 years.
Seattle, WashingtonAges 18 years+ - NCT07654283RecruitingPhase 2
Study of AHB-137 for chronic hepatitis B
This trial tests a new drug, AHB-137, in people with chronic hepatitis B who are already on a stable antiviral treatment. It aims to see if AHB-137 can help lower the virus further or improve outcomes.
Palo Alto, CaliforniaAges 18–65 - NCT07642076RecruitingPhase 4
L-carnitine supplement for critically ill liver disease patients
This study tests whether adding L-carnitine (a naturally occurring compound) to standard care helps people with serious liver disease who are in the intensive care unit. L-carnitine may help the body use energy better and reduce complications from liver failure.
Shibīn al KawmAges 18 years+ - NCT07630727RecruitingPhase 2
AHB-171 treatment for chronic hepatitis B
This study tests whether a new drug called AHB-171 can help treat chronic hepatitis B (a long-term liver infection). You would receive the drug by injection under your skin and be monitored to see if it helps reduce the hepatitis B virus and improves liver health.
Beijing, Beijing MunicipalityAges 18–65 - NCT07635186RecruitingPhase 2
AHB-137 injection for treatment-naïve chronic hepatitis B
This study tests a new injection called AHB-137 in people with chronic hepatitis B who have never received antiviral treatment. The goal is to see if it can help reduce the hepatitis B virus in the body and improve liver health.
Beijing, Beijing MunicipalityAges 18–65 - NCT06696664Recruiting
Genetic study of chronic hepatitis B cure with long-acting interferon
This study looks at genetic factors that may help people with chronic hepatitis B achieve a clinical cure when treated with long-acting interferon. It aims to find out why some patients respond better than others.
Beijing, Beijing MunicipalityAges 18–70 - NCT04310787Recruiting
Tracking outcomes in adults with hepatitis B liver failure
This study looks at long-term survival in people ages 18–65 who are hospitalized with hepatitis B–related acute-on-chronic liver failure. It may help doctors better predict prognosis and improve care for people with this serious condition.
Guangzhou, GuangdongAges 18–65 - NCT02883647Recruiting
Stopping antiviral treatment in chronic hepatitis B
This trial studies what happens after stopping long-term hepatitis B antiviral medicine in people whose virus has stayed controlled. It also follows patients over time to see how well they remain stable and safe after stopping.
Guangzhou, GuangdongAges 18–65 - NCT07606950RecruitingPhase 3
Testing HRS-5635 to improve hepatitis B treatment
This study tests whether adding a new drug called HRS-5635 to your current hepatitis B medicine works better than your current treatment alone. You may qualify if your hepatitis B is already controlled with antiviral pills and your viral levels are very low.
Guangzhou, GuangzhouAges 18 years+ - NCT06718153Recruiting
Using protein tests to diagnose liver cancer types
This trial uses special stains on tumor tissue to find genetic changes in liver cancer cells. It may help doctors better diagnose and classify the type of liver cancer you have.
BolognaAges 18 years+ - NCT07573943RecruitingPhase 4
ASC22 with Peg-IFN for chronic hepatitis B cure
This study tests whether a combination of two drugs (ASC22 and Peg-IFN) can help people with chronic hepatitis B achieve a functional cure. The goal is to see if this therapy can clear the virus and improve liver health.
Chongqing, Chongqing MunicipalityAges 18–60 - NCT05368974Recruiting
Pregnancy registry for hepatitis C treatment timing
This study is a pregnancy registry that collects information about people who have hepatitis C during pregnancy and took hepatitis C medicines early in pregnancy. It aims to better understand the safety and outcomes of treatment around conception.
Atlanta, GeorgiaAges Any age - NCT07558681Recruiting
Antibiotic dosing during liver and pancreas surgery
This study checks if the standard dose of an antibiotic (piperacillin/tazobactam) reaches effective levels in the blood during major liver or pancreas surgery. The goal is to improve infection prevention after surgery.
Vandœuvre-lès-Nancy, LorraineAges 18 years+ - NCT07559474RecruitingPhase 1
Safety Study of INCB123667 in Adults With Liver Damage
This study tests how a new experimental medicine (INCB123667) works and is tolerated in adults with moderate to severe liver problems. Researchers want to understand how the body processes this drug and whether it's safe in people with liver dysfunction.
Chandler, ArizonaAges 18–80 - NCT07546760RecruitingPhase 1
Study of how liver disease affects two new medications
This research study tests how two experimental drugs (AZD9550 and AZD6234) work in people with different levels of liver function. The goal is to understand whether liver disease changes how the body processes these medications, which may help doctors safely treat patients with liver problems in the future.
Chandler, ArizonaAges 18–85 - NCT07519330RecruitingPhase 2
Testing HH-006 treatment for chronic hepatitis B
This study tests a new drug called HH-006 to see if it can help treat chronic hepatitis B infection. Participants will be grouped by their infection level, and the study checks whether the drug is safe and works to reduce the hepatitis B virus.
Chongqing, Chongqing MunicipalityAges 18–45 - NCT07511218RecruitingPhase 1
Study of AHB-171 for stable chronic hepatitis B
This trial tests a new investigational drug called AHB-171 for people with chronic hepatitis B who are already stable on standard antiviral therapy. It aims to see if the drug is safe and may help control the virus better.
Ch’ang-ch’un, JilinAges 18–65 - NCT06761261Recruiting
Acute Hepatitis in Children Study
This trial is for children and teens (0–17 years) who are in the hospital or emergency department with acute hepatitis (sudden liver inflammation). The study aims to learn more about the condition and how to best treat it.
BolognaAges Up to 17 years - NCT06761209Recruiting
Autoantibody negativity and autoimmune hepatitis severity
This trial checks if the absence of certain antibodies in autoimmune hepatitis (AIH) is linked to more severe disease. It may help doctors better understand and treat AIH.
Paris, FranceAges 18 years+ - NCT07504471RecruitingPhase 2
Bicarbonate plus chemo and immunotherapy for pancreatic cancer liver spread
This trial tests adding sodium bicarbonate to a chemotherapy plus immunotherapy regimen for pancreatic cancer that has spread to the liver. The goal is to see if this combination helps shrink tumors and improves outcomes.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06122285Recruiting
Bulevirtide for chronic hepatitis delta
This study tests a daily shot of Bulevirtide for people with long-term hepatitis delta and early-stage cirrhosis. It aims to see if the medicine is safe and works well.
Milan, MIAges 18 years+ - NCT07487623Recruiting
Nutritional supplement for liver protection in hepatitis C
This trial tests whether a special nutritional supplement can protect the liver in people with chronic hepatitis C. If you have mild to moderate liver damage and meet the criteria, you may be able to join.
Guadalajara, JaliscoAges 18–69 - NCT06779864Recruiting
Hepatitis B virus genetics and drug resistance study
This study looks at how hepatitis B virus changes in your body, including mutations and drug resistance, using your blood or liver tissue samples. Understanding these changes could help improve treatment for hepatitis B.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07457229RecruitingPhase 1
Study of Radiprodil in People With Liver Problems
This study tests a drug called radiprodil in people with different levels of liver problems. It helps doctors understand how the liver processes the drug, which could make future treatments safer.
DeSoto, TexasAges 18–75
Hear when a new Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatitis?
- Yes. Clin2 currently lists 480 recruiting hepatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.